Skip to content
CancerIndex

Year in cancer

2001 in cancer

What the index holds for 2001: regulatory decisions dated that year, studies first posted that year, PubMed output per cancer for that year and the registry observations whose reference year it is. Every figure is a count of dated source records — nothing is estimated.

Regulatory

Approval records dated 2001 (25)

Approved, accelerated or conditional records by authority; original applications and records naming one cancer are listed first. One record is one decision for one application or product identifier.

FDA · US: 16 records / 11 drugsEMA · EU: 5 records / 5 drugsHealth Canada · CA: 4 records / 3 drugs

  • Sep 18, 2001Flutamide FDA · US original application approved Prostate CarcinomaEulexin ® capsules are indicated for use in combination with LHRH-agonists for the management of locally confined Stage B 2 -C and Stage D 2 metastatic…openfda
  • Jun 29, 2001Triptorelin FDA · US original application approved Malignant Prostate NeoplasmTRELSTAR is indicated for the treatment of advanced prostate cancer [ see Clinical Studies (14) ]. TRELSTAR is a gonadotropin releasing hormone (GnRH) agonist…openfda
  • May 7, 2001Alemtuzumab FDA · US original application approved Chronic Lymphocytic LeukemiaCAMPATH is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). CAMPATH is a CD52-directed cytolytic antibody…openfda
  • Oct 24, 2001Temoporfin EMA · EU centralised approved Head and Neck Squamous Cell CarcinomaFoscan is indicated for the palliative treatment of patients with advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for…ema
  • Mar 29, 2001Bexarotene EMA · EU centralised approved Primary Cutaneous T-Cell Non-Hodgkin LymphomaTargretin capsules are indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least…ema
  • Dec 11, 2001Trastuzumab FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2001-12-11 (see label)openfda
  • Nov 7, 2001Imatinib EMA · EU centralised approved cancer not stated in this recordGlivec is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia-chromosome (bcr-abl)-positive (Ph+) chronic myeloid…ema
  • Oct 31, 2001Paclitaxel Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as PACLITAXEL FOR INJECTION (DIN 02244372) under ATC L01CD01 PACLITAXEL. Indications are not published in the Drug Product Database — see…health-canada-dpd
  • Oct 18, 2001Celecoxib FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2001-10-18 (see label)openfda
  • Oct 12, 2001Sertraline FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2001-10-12 (see label)openfda
  • Oct 12, 2001Sertraline FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2001-10-12 (see label)openfda
  • Sep 21, 2001Leuprolide FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2001-09-21 (see label)openfda
  • Sep 21, 2001Leuprolide FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2001-09-21 (see label)openfda
  • Sep 7, 2001Capecitabine FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2001-09-07 (see label)openfda
  • Aug 22, 2001Verteporfin FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2001-08-22 (see label)openfda
  • Aug 6, 2001Sertraline FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2001-08-06 (see label)openfda
  • Aug 6, 2001Sertraline FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2001-08-06 (see label)openfda
  • May 26, 2001Irbesartan FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2001-05-26 (see label)openfda
  • Apr 30, 2001Capecitabine FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2001-04-30 (see label)openfda
  • Mar 20, 2001Ifosfamide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as IFEX (DIN 02241357) under ATC L01AA06 IFOSFAMIDE. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
  • Mar 20, 2001Zoledronic Acid EMA · EU centralised approved cancer not stated in this recordPrevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients…ema
  • Feb 22, 2001Hydroxyurea Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as MYLAN-HYDROXYUREA (DIN 02242920) under ATC L01XX05 HYDROXYCARBAMIDE. Indications are not published in the Drug Product Database — see the…health-canada-dpd
  • Feb 2, 2001Capecitabine EMA · EU centralised approved cancer not stated in this recordXeloda is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer. Xeloda is indicated for the treatment…ema
  • Jan 25, 2001Ifosfamide Health Canada · CA DIN approved cancer not stated in this recordMarketed in Canada as IFEX (DIN 02241356) under ATC L01AA06 IFOSFAMIDE. Indications are not published in the Drug Product Database — see the Health Canada…health-canada-dpd
  • Jan 10, 2001Letrozole FDA · US supplement approved cancer not stated in this recordEfficacy supplement 2001-01-10 (see label)openfda

RegulatoryAll 2001 records with filters →

Clinical research

Studies first posted in 2001

ClinicalTrials.gov oncology studies whose first-posted date falls in the year (all study types unless stated). Cancer attribution uses reconciled conditions over descendants; one study can count for several top-level cancers.

Studies
152
Interventional
116
Phase III
18
Industry-led
51
With posted results
4
Countries with sites
9
By phase (a study with two phases counts in both)
PhaseStudiesInterventionalIndustry share
Early Phase 1110%
Phase 1414146%
Phase 2444445%
Phase 3181839%
Not applicable / not stated531715%
Top-level cancers by studies (descendants included)
CancerStudiesPhase III
Kaposi Sarcoma426
Non-Hodgkin Lymphoma201
Leukemia90
Malignant Prostate Neoplasm91
Malignant Breast Neoplasm80
Malignant Central Nervous System Neoplasm40
Malignant Kidney Neoplasm20
Hodgkin Lymphoma20
Malignant Lung Neoplasm20
Malignant Laryngeal Neoplasm20
Malignant Bladder Neoplasm20
Malignant Uterine Corpus Neoplasm10
Lead sponsors of interventional studies first posted in 2001
Lead sponsorClassStudiesPhase III
National Institute of Allergy and Infectious Diseases (NIAID)Nih325
National Cancer Institute (NCI)Nih120
INSYS Therapeutics IncIndustry70
US Department of Veterans AffairsFed71
Corixa CorporationIndustry60
Daiichi PharmaceuticalsIndustry40
Sequus PharmaceuticalsIndustry44
Anderson Clinical ResearchIndustry20
Lederle LaboratoriesIndustry20
Glaxo WellcomeIndustry20

Published source: clinicaltrials · first_posted_date as posted